Chasing Miracles of Science
In the journey to good health, you need the right partner
Our Stories…
MAT-IN-2201708-1.0-07/22. All images shown are for illustration purpose only. Only for registered medical practitioners.Looking for medical and scientific content that's trusted, relevant, and curated for registered HCPs?
MAT-IN-2400282-1.0-02/2024Want to control diabetes better?
About us
100,000+ employees representing 145 nationalities, striving to provide healthcare solutions in 170+ countries!
In India since 1956, we offer innovative solutions in preventive healthcare (vaccines) as well as in treatment for allergy, pain, diabetes, rare diseases, and other therapeutic areas.
Why join Sanofi?
"Here, when you reach out to your mentors for more challenging roles, they carve out a journey for you across roles, departments and geographies."
Unnati Umrootkar - Analytics & Value Activation Controller, Sanofi Business Services
Media Release
Diabetes awareness program in Goa’s schools sparking lifestyle changes to tackle rising Obesity trend
Announcement December 09 2023
Through this Social Impact collaboration, Sanofi India’s team of medical experts and local leading diabetologists have been educating and upskilling the State department’s healthcare personnel serving the Rashtriya Bal Swasthya Karyakram (RBSK) cell; and the Medical Officers of the Health and Wellness centers.
Dupixent® (dupilumab) is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis
Announcement July 11 2023
Sanofi Healthcare India Pvt. Ltd. has received marketing authorization for Dupixent® (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Sanofi receives marketing approval for its diabetes drug Soliqua™ in India
Announcement March 27 2023
Sanofi (India) announced that it has received marketing authorization for its diabetes drug Soliqua™ (in pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO).
Contact us
For seeking medical information, reporting adverse events and product complaints: 1800 22 2295 (toll-free) For other queries: 022-28032000
For medical information: medinfo.india@sanofi.com, customercare.chc@sanofi.com (Consumer healthcare products)
For reporting adverse events: PV.india@sanofi.com
For product complaints: ptcindia@sanofi.com
For other queries: Write here
Beware of Fraudsters
Beware of fraudsters who might intend to deceive you financially or otherwise by unauthorisedly using Sanofi’s name or logo and/or offering fake or counterfeit medicines; and/or by sharing fake apps, videos, games or other such assets. You are advised to immediately raise this before an appropriate cyber cell/police, should you face any such concern.
Few ways to recognize this:
The video/app/photo/game you view is not hosted on an official Sanofi channel (like @IndiaSanofi on Facebook or @Sanofi on Instagram or @IndiaSanofi on Twitter or @Sanofi on LinkedIn) The communication you may receive, appears unprofessional, containing poor grammar and/or typos Emails or other communication is not sent from a Sanofi address (please note that legitimate emails end only with a ‘@sanofi.com’ extension and procurement of company products is only through authorized Sanofi distributor channels) Inspite of a product shortage, if you are promised the product delivery at short notice, in exchange of an immediate online transfer or cash If you have any such concern, please write to us through the above channel.
All consumers or patients are advised to contact their doctor or healthcare professional for advice on medicines or any health matters/medical emergencies.
You can email or call us between 9 AM and 5 PM on any working day (we are closed on Saturday, Sunday and public holidays). Please select IVRS option 3 for reporting adverse events.